'Often Reserved' FDA Biologics Chief Midthun To Depart
This article was originally published in Scrip
Executive Summary
Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research (CBER), is retiring from the agency, acting Commissioner Stephen Ostroff and his intended successor, Robert Califf, deputy commissioner for medical products and tobacco, confirmed to their staff on Oct. 2, declaring they had "mixed emotions" about her departure.